ClinicalTrials.gg
Status unknownNCT04229615Updated Apr 25, 2022

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

A Phase 3 interventional study of Fluzoparib; Apatinib and Fluzoparib in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing fluzoparib in Ovarian Neoplasms — 13 open to participants now, 13 under way, 1 of them phase 3. fluzoparib · Ovarian Neoplasms.

Enrollment
Largest of 22
690 · median 70
Started
2020
with 1 other
Phase 3
3 of 22
1 open now
Registered
5th of 22
by date
Lead sponsor
7 of 22
Jiangsu HengRui Medicine Co., Ltd.

Among the 22 studies testing fluzoparib in Ovarian Neoplasms, this one has the largest enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 5th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 22 studies testing fluzoparib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About fluzoparib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing fluzoparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer. Patients must have completed first-line platinum based regimen with Complete Response (CR) or Partial Response (PR). The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (phase 3)Histologically new diagnosed, advanced (FIGO Stage III or IV) high-grade serous or endometrioid ovarian cancer (including primary peritoneal and fallopian tube cancer)
  • (phase 3)Complete response (CR) or partial response (PR) achieved with front-line platinum-based chemotherapy regimen as determined by investigator
  • (phase 3)Ability to be randomized ≤8 weeks after last dose of platinum
  • (Saftey Lead-in)Received 2\~4 prior chemotherapy regimens. Platimun sensitive ; Have at least one as defined by v1.1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib
  • Patients who have received other study drug treatment within 4 weeks prior to the first administration(\< 5 elimination half-lives of the study drug molecular targeted anti-cancer drugs).
  • Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 2 months prior to the first administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
690 participants (actual)

Study arms

  • Experimental
    Safety Lead-in, Doublet Arm

    Fluzoparib+Apatinib

    Drug: Fluzoparib; Apatinib

  • Experimental
    Single Arm

    Fluzoparib

    Drug: Fluzoparib

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugFluzoparib; Apatinib

    Drug pages: Fluzoparib · Apatinib

    Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily

  • Fluzoparib Orally twice daily

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. (Safety Lead-in) Incidence of ≥3 grade TRAEs

    Incidence of ≥3 grade treatment related adverse events

    Time frame: up to 28 days after the last patient of the lead-in phase

  2. (Phase 3) Progression free survival(PFS) in advanced ovarian cancer patients

    Defined as progression free survival per RECIST 1.1 criteria according to BIRC criteria

    Time frame: up to 4 years

Secondary outcomes

  1. AEs+SAEs

    Adverse Events and Serious Adverse Events

    Time frame: from the first drug administration to within 30 days for the last treatment dose

  2. PFS by investigator's assessment

    Progression-Free-Survival

    Time frame: up to 4 years

  3. OS

    OS is the time interval from the start of treatment to death due to any reason or lost of follow-up

    Time frame: up to 6 years

  4. Patients reported outcome(PROs)assessed by EQ-5D-5L questionnaire

    Comparison of the Quality of Life in study arms assessed by EQ-5D-5L questionnaire

    Time frame: 48 months

  5. Patients reported outcome(PROs)assessed by FOSI questionnaire

    Comparison of the Quality of Life in study arms assessed by FOSI questionnaire

    Time frame: 48 months

  6. Time to progression on the next anticancer therapy (PFS2) From date of start of next anticancer therapy to date of first documented progression of date of death from any cause, whichever comes first.

    From date of start of next anticancer therapy to date of first documented progression of date of death from any cause, whichever comes first.

    Time frame: 4 years

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2023, 36 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 36 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2020
First posted
Jan 18, 2020
StartActual
Jun 2, 2020
Primary completionEst.
Jun 30, 2023
CompletionEst.
Apr 1, 2024
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04229615
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jun 2, 2020
Primary completion
Jun 30, 2023 (estimated)
Completion
Apr 1, 2024 (estimated)
Last update
Apr 25, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluzoparib · Apatinib

Start the discussion